Author

Christiane Falge

Observed names: C Falge, C. Falge, Falge, C, Falge, C., Falge, Christiane

Institution: Nuremberg Hospital

Observed institutions: Philipps University of Marburg, Heidelberg University, Universitätsklinikum Gießen und Marburg, University Hospital Heidelberg, Universitätsklinikum Tübingen, Nuremberg Hospital, Jena University Hospital, University Hospital Ulm, University Medical Centre Mannheim, Medizinische Fakultät Mannheim, University of Tübingen

OpenAlex ID: A5044783231

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

2012 · B Hanfstein, M C Müller, et al. · Leukemia · 420

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

2017 · for the SAKK and the German CML Study Group, R Hehlmann, et al. · Leukemia · 349

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

2013 · Rüdiger Hehlmann, Martin C. Müller, et al. · Journal of Clinical Oncology · 302

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

2011 · Alice Fabarius, Armin Leitner, et al. · Blood · 288

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

2015 · L Kalmanti, S Saussele, et al. · Leukemia · 280

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

2009 · Susanne Saussele, Michael Lauseker, et al. · Blood · 216

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

2007 · Rüdiger Hehlmann, Ute Berger, et al. · Blood · 161

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

2014 · B Hanfstein, V Shlyakhto, et al. · Leukemia · 139

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

2014 · B. Hanfstein, M. Lauseker, et al. · Haematologica · 123

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

2020 · Rüdiger Hehlmann, Astghik Voskanyan, et al. · Leukemia · 92

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML

2015 · for the SAKK and the German CML Study Group, Alice Fabarius, et al. · Annals of Hematology · 83

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV

2013 · German Chronic Myeloid Leukemia Study Group, Lida Kalmanti, et al. · Annals of Hematology · 78

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

2015 · for the SAKK and the German CML Study Group, A Gratwohl, et al. · Leukemia · 57

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV

2018 · Susanne Saussele, Rüdiger Hehlmann, et al. · Leukemia · 34

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

2018 · Christian Michel, Andreas Burchert, et al. · Haematologica · 23

The German CML Study, Comparison of Busulfan vs. Hydroxyurea vs. Interferon alpha and Establishment of Prognostic Score 1

1993 · R. Hehlmann, H. Heimpel, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16

Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV

2011 · Benjamin Hanfstein, Martin C. Müller, et al. · Blood · 14

Long-term correction of neutropenia in Felty's syndrome with granulocyte colony-stimulating factor

1993 · H. Wandt, M. Seifert, et al. · Annals of Hematology · 13

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV

2014 · Susanne Saussele, Michael Lauseker, et al. · Blood · 9

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

2017 · Rüdiger Hehlmann, Michael Lauseker, et al. · Blood · 8

Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia

2014 · for the Schweizerische Arbeitsgemeinschaft für Klinische Forschung (SAKK) and the German CML Study Group, Markus Pfirrmann, et al. · Journal of Cancer Research and Clinical Oncology · 7

The prognostic significance of early molecular and cytogenetic response for long-term progression-free and overall survival in imatinib-treated chronic myeloid leukemia (CML).

2012 · Rudiger Hehlmann, Benjamin Hanfstein, et al. · Journal of Clinical Oncology · 7

Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV

2010 · Rüdiger Hehlmann, Susanne Jung-Munkwitz, et al. · Blood · 7

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML

2020 · Rüdiger Hehlmann, Astghik Voskanyan, et al. · Leukemia · 6

Secondary Malignancies in CML Patients – Data From the German CML Study IV

2012 · Manuel Barreto Miranda, Michael Lauseker, et al. · Blood · 6

Works count: 61

Citation count: 2,779

H-index: 16

I10-index: 18